1. >
  2. Company
  3. >
  4. Profile

PROFILE

Onxeo is a  clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions.

Our therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. Our approach is based upon unique mechanisms of action on DNA Damage Response. We focus on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

We seek to transform breakthrough scientific opportunities into treatments through translational and clinical expertise, developing products to the stage where they are compelling opportunities for partners. Therefore, we are focused on advancing products from preclinical stage to optimal inflection points (usually phase 2 clinical proof-of-concept studies). Once proof of concept is established, we seek to monetize the assets through various types of deals, thereby generating revenue and value.

Our inherent value rests on the significant potential of our product pipeline and the expertise of our highly professional team.


OUR PEOPLE

We are a passionate team of scientists and business professionals,  with robust in-house translational and clinical expertise to drive our programs to their maximum value-inflection points and generate value and growth through collaborations.

We are led by a senior management team with extensive life sciences industry experience in international venues and a proven track record in translational research, clinical development, regulatory affairs and business development.


OUR SCIENCE

Our proprietary platform of decoy oligonucleotides, platON™, generates innovative compounds targeting tumor DNA repair functions through a decoy mechanism with an agonist effect.

This mechanism of action is unlike any other investigated or available today in this field. It has the capacity to address new & multiple DNA repair pathways and to target the DNA Damage Response without inducing resistance.


OUR PROGRAMS

platON™ has already generated two very innovative molecules.

  • AsiDNA™ is a first-in-class DDR inhibitor, currently in clinical trials. Thanks to its very differentiated ability to abrogate tumor acquired resistance, AsiDNA™ could be used in multiple therapeutic applications, notably in combination with DNA-damaging treatments as well as targeted therapies. Unlike inhibitors of a single DDR pathway or protein such as PARP inhibitors, AsiDNA™ acts upstream of multiple pathways, to divert DNA repair proteins from their true targets without inducing resistance. Thanks to a good safety profile, AsiDNA™ is particularly amenable to combination treatment, a standard of care in aggressive or resistant cancers. AsiDNA™ is currently evaluated in a phase 1b study in combination with chemotherapy and in the phase 1b/2 REVOCAN study in addition to PARP inhibitor niraparib in relapsed ovarian cancer.
  • OX401 is the newest addition in the pipeline, currently undergoing preclinical proof of concept studies, alone and in combination with checkpoint inhibitors. At the crossroads of DNA damage response and immunotherapy, OX401 is designed to be a PARP agonist that does not induce resistance but triggers a strong immune response through the activation of the STING pathway.

 


OUR INVESTORS

Onxeo is a public company, listed on Euronext Growth Paris (Ticker ALONX) and on Nasdaq First North Copenhagen (Ticker ONXEO) : ISIN FR0010095596.

We strive to provide our investors with ongoing and transparent information beyond regulatory guidelines.


OUR HISTORY